Engineered immune cells target tough leukemia in new trial

NCT ID NCT07252336

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests a treatment called CD19 CAR-T cell therapy in 50 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The therapy uses a patient's own immune cells, modified to find and attack leukemia cells. The main goal is to see if the treatment can make the leukemia disappear at a molecular level, and researchers will also track how long patients stay cancer-free and their overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of medical college of zhejiang university

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.